India’s opportunity to build preventive healthcare economy
The country’s strength lies not just in technology availability but in adoption behaviour
The country’s strength lies not just in technology availability but in adoption behaviour
The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
Access to genomic testing, not therapy cost, is the biggest challenge
Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
The target reach is of more than 30 million young people and caregivers across 21 countries
Global specialty pipeline accelerates growth
Subscribe To Our Newsletter & Stay Updated